Prevalance Of Helicobacter Pylori Infection In Chonic Kidney Diseased Patient Admitted To Luxor Medical Complex

April 13, 2024 updated by: Gehad Abdel Shafy Ahmed Abdel kader, Assiut University

Prevalance Of Helicobacter Pylori Infection In Chonic Kidney Diseased Patient Admitted To Luxor Medical

Detect prevalence of Helicobacter pylori infection in chronic kidney diseased patient admitted to Luxor medical complex and possible role of Helicobacter pylori in pathogenesis of chronic kidney diseased patient of unknown etiology

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Helicobacter Pylori bacteria is the main pathogenic organism that settles on the gastric mucosa of more than half the human population around the world, with more prominence in the developing countries. H. Pylori had been found to be the main factor in acute and chronic gastritis, peptic ulcer diseases, and in most cases gastric malignancy. Beside to some extra gastro-intestinal diseases. Such as cardiac, pulmonary, renal and hematological diseases.

Another study showed a significant higher proteinuria in H. Pylori infected patients compared to non-infected individuals. Helicobacter pylori is a gram-negative bacterium infecting both children and adults. It is the most common human chronic infection, causing gastrointestinal diseases such as gastric malignancies, gastritis, and ulcerative diseases. H. pylori can also be involved in other non gastrointestinal infections such as diabetes and metabolic syndrome, heart disease, hematologic disorders, cancer, and chronic kidney disease (CKD) as well as chronic renal failure (CRF).

Some chronic renal failure patients who have received hemodialysis for long periods complained of gastrointestinal troubles. It has been postulated that high urea concentration makes the gastric mucosa of these patients more susceptible to H. pylori colonization. Previous observations in different countries reported the prevalence of H. pylori infection among patients with CRF ranging between 20 and 60%, and H. pylori infection can contribute to progressive renal dysfunction resulting in CKD development. In patients without established gastric dysfunction, the presence of H pylori infection was associated with increased risk for Chronic kidney dusease however, patients with both atrophic gastritis (AG) and Helcobacter pylori infection appeared to be at decreased risk for Chronic kidney disease compared with control participants.

For the H. pylori-positive patients with peptic ulcer, H. pylori infection may be a risk factor resulting in kidney damage and H. pylori eradication probably benefits to kidney damage relief and chronic kidney disease prevention.

Study Type

Observational

Enrollment (Estimated)

122

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Prevalance Of Helicobacter Pylori Infection In Chonic Kidney Diseased Patient Admitted To Luxor Medical complex hospital

Description

Inclusion Criteria:

  • All patients aged >18 years old with chronic kidney disease of different etiology based on clinical examination, laboratory investigations and imaging

Exclusion Criteria:

  1. Patients aged ≤18 years old.
  2. Overloaded patients
  3. patient with acute kidney injury
  4. Patients with other GIT disease
  5. pregnant female
  6. patient taking aspirin, NSAID, steroid or antibiotic
  7. Presence of malignancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
prevalence of helicobacter pylori in chronic kidney diseased patient
Other: disease
Helicobacter Pylori Infection In Chonic Kidney Diseased Patien
prevalence of helicobacter pylori in non chronic kidney diseased patient
Other: disease
Helicobacter Pylori Infection In Chonic Kidney Diseased Patien

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Helicobacter pylori infection and Chronic kidney diseased patient
Time Frame: 1 year
Detect prevalence of H pylori infection in chronic kidney diseased patient admitted to Luxor medical complex hospital
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
possible role of H pylori in pathogenesis of chronic kidney diseased patient of unkown etiology
Time Frame: 1 year
possible role of H pylori in pathogenesis of chronic kidney diseased patient of unkown etiology
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2024

Primary Completion (Estimated)

May 1, 2025

Study Completion (Estimated)

July 1, 2025

Study Registration Dates

First Submitted

April 13, 2024

First Submitted That Met QC Criteria

April 13, 2024

First Posted (Actual)

April 17, 2024

Study Record Updates

Last Update Posted (Actual)

April 17, 2024

Last Update Submitted That Met QC Criteria

April 13, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Helicobacter Pyloi and CKD

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Kidney Diseases

Clinical Trials on disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe